ACADIA Pharmaceuticals Inc.
ACAD
Rank in Stocks
#4463
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Share Price
$20.16
Market Cap
$3.47B
Change (1 day)
-1.35%
Change (1 year)
-5.20%
Country
US
Trade ACADIA Pharmaceuticals Inc. (ACAD)
Category
Healthcare
Stock price history for ACADIA Pharmaceuticals Inc. (ACAD)
Highest end of day price: $19.68 on 2026-10-01
Lowest end of day price: $6.66 on 2004-05-01
Lowest end of day price: $6.66 on 2004-05-01
Stock price history of ACADIA Pharmaceuticals Inc. from 2004 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -10.49% |
| 2025 | 55.58% |
| 2024 | -35.30% |
| 2023 | 74.02% |
| 2022 | -32.82% |
| 2021 | -57.69% |
| 2020 | 18.76% |
| 2019 | 165.62% |
| 2018 | -42.16% |
| 2017 | 8.65% |
| 2016 | -22.24% |
| 2015 | 11.41% |
| 2014 | 29.97% |
| 2013 | 416.58% |
| 2012 | 328.70% |
| 2011 | 23.06% |
| 2010 | -30.48% |
| 2009 | 14.05% |
| 2008 | -90.54% |
| 2007 | 30.89% |
| 2006 | -8.44% |
| 2005 | 48.01% |
| 2004 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
